These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

318 related articles for article (PubMed ID: 31353261)

  • 1. Targeting Pathogenic Lafora Bodies in Lafora Disease Using an Antibody-Enzyme Fusion.
    Brewer MK; Uittenbogaard A; Austin GL; Segvich DM; DePaoli-Roach A; Roach PJ; McCarthy JJ; Simmons ZR; Brandon JA; Zhou Z; Zeller J; Young LEA; Sun RC; Pauly JR; Aziz NM; Hodges BL; McKnight TR; Armstrong DD; Gentry MS
    Cell Metab; 2019 Oct; 30(4):689-705.e6. PubMed ID: 31353261
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Central Nervous System Delivery and Biodistribution Analysis of an Antibody-Enzyme Fusion for the Treatment of Lafora Disease.
    Austin GL; Simmons ZR; Klier JE; Rondon A; Hodges BL; Shaffer R; Aziz NM; McKnight TR; Pauly JR; Armstrong DD; Vander Kooi CW; Gentry MS
    Mol Pharm; 2019 Sep; 16(9):3791-3801. PubMed ID: 31329461
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Polyglucosan body structure in Lafora disease.
    Brewer MK; Putaux JL; Rondon A; Uittenbogaard A; Sullivan MA; Gentry MS
    Carbohydr Polym; 2020 Jul; 240():116260. PubMed ID: 32475552
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lack of p62 Impairs Glycogen Aggregation and Exacerbates Pathology in a Mouse Model of Myoclonic Epilepsy of Lafora.
    Pellegrini P; Hervera A; Varea O; Brewer MK; López-Soldado I; Guitart A; Aguilera M; Prats N; Del Río JA; Guinovart JJ; Duran J
    Mol Neurobiol; 2022 Feb; 59(2):1214-1229. PubMed ID: 34962634
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An inducible glycogen synthase-1 knockout halts but does not reverse Lafora disease progression in mice.
    Nitschke S; Chown EE; Zhao X; Gabrielian S; Petković S; Guisso DR; Perri AM; Wang P; Ahonen S; Nitschke F; Minassian BA
    J Biol Chem; 2021; 296():100150. PubMed ID: 33277363
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacological Interventions to Ameliorate Neuropathological Symptoms in a Mouse Model of Lafora Disease.
    Berthier A; Payá M; García-Cabrero AM; Ballester MI; Heredia M; Serratosa JM; Sánchez MP; Sanz P
    Mol Neurobiol; 2016 Mar; 53(2):1296-1309. PubMed ID: 25627694
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Suppression of glycogen synthesis as a treatment for Lafora disease: Establishing the window of opportunity.
    Varea O; Duran J; Aguilera M; Prats N; Guinovart JJ
    Neurobiol Dis; 2021 Jan; 147():105173. PubMed ID: 33171226
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ppp1r3d deficiency preferentially inhibits neuronal and cardiac Lafora body formation in a mouse model of the fatal epilepsy Lafora disease.
    Israelian L; Nitschke S; Wang P; Zhao X; Perri AM; Lee JPY; Verhalen B; Nitschke F; Minassian BA
    J Neurochem; 2021 Jun; 157(6):1897-1910. PubMed ID: 32892347
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Modulators of Neuroinflammation Have a Beneficial Effect in a Lafora Disease Mouse Model.
    Mollá B; Heredia M; Sanz P
    Mol Neurobiol; 2021 Jun; 58(6):2508-2522. PubMed ID: 33447969
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The 5th International Lafora Epilepsy Workshop: Basic science elucidating therapeutic options and preparing for therapies in the clinic.
    Gentry MS; Afawi Z; Armstrong DD; Delgado-Escueta A; Goldberg YP; Grossman TR; Guinovart JJ; Harris F; Hurley TD; Michelucci R; Minassian BA; Sanz P; Worby CA; Serratosa JM
    Epilepsy Behav; 2020 Feb; 103(Pt A):106839. PubMed ID: 31932179
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ontogeny of Lafora bodies and neurocytoskeleton changes in Laforin-deficient mice.
    Machado-Salas J; Avila-Costa MR; Guevara P; Guevara J; Durón RM; Bai D; Tanaka M; Yamakawa K; Delgado-Escueta AV
    Exp Neurol; 2012 Jul; 236(1):131-40. PubMed ID: 22542948
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinicopathologic Dissociation: Robust Lafora Body Accumulation in Malin KO Mice Without Observable Changes in Home-Cage Behavior.
    Krishnan V; Wu J; Mazumder AG; Kamen JL; Schirmer C; Adhyapak N; Bass JS; Lee SC; Maheshwari A; Molinaro G; Gibson JR; Huber KM; Minassian BA
    J Comp Neurol; 2024 Jul; 532(7):e25660. PubMed ID: 39039998
    [TBL] [Abstract][Full Text] [Related]  

  • 13. AAV-Mediated Artificial miRNA Reduces Pathogenic Polyglucosan Bodies and Neuroinflammation in Adult Polyglucosan Body and Lafora Disease Mouse Models.
    Gumusgoz E; Kasiri S; Guisso DR; Wu J; Dear M; Verhalen B; Minassian BA
    Neurotherapeutics; 2022 Apr; 19(3):982-993. PubMed ID: 35347645
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Laforin prevents stress-induced polyglucosan body formation and Lafora disease progression in neurons.
    Wang Y; Ma K; Wang P; Baba O; Zhang H; Parent JM; Zheng P; Liu Y; Minassian BA; Liu Y
    Mol Neurobiol; 2013 Aug; 48(1):49-61. PubMed ID: 23546741
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Astrocytes and neurons produce distinct types of polyglucosan bodies in Lafora disease.
    Augé E; Pelegrí C; Manich G; Cabezón I; Guinovart JJ; Duran J; Vilaplana J
    Glia; 2018 Oct; 66(10):2094-2107. PubMed ID: 30152044
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The 6th International Lafora Epilepsy Workshop: Advances in the search for a cure.
    Markussen KH; Macedo JKA; Machío M; Dolce A; Goldberg YP; Vander Kooi CW; Gentry MS
    Epilepsy Behav; 2021 Jun; 119():107975. PubMed ID: 33946009
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Genetic depletion of the malin E3 ubiquitin ligase in mice leads to lafora bodies and the accumulation of insoluble laforin.
    DePaoli-Roach AA; Tagliabracci VS; Segvich DM; Meyer CM; Irimia JM; Roach PJ
    J Biol Chem; 2010 Aug; 285(33):25372-81. PubMed ID: 20538597
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The carbohydrate-binding domain of Lafora disease protein targets Lafora polyglucosan bodies.
    Ganesh S; Tsurutani N; Suzuki T; Hoshii Y; Ishihara T; Delgado-Escueta AV; Yamakawa K
    Biochem Biophys Res Commun; 2004 Jan; 313(4):1101-9. PubMed ID: 14706656
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibiting glycogen synthesis prevents Lafora disease in a mouse model.
    Pederson BA; Turnbull J; Epp JR; Weaver SA; Zhao X; Pencea N; Roach PJ; Frankland PW; Ackerley CA; Minassian BA
    Ann Neurol; 2013 Aug; 74(2):297-300. PubMed ID: 23913475
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The phosphatase activity of laforin is dispensable to rescue Epm2a-/- mice from Lafora disease.
    Gayarre J; Duran-Trío L; Criado Garcia O; Aguado C; Juana-López L; Crespo I; Knecht E; Bovolenta P; Rodríguez de Córdoba S
    Brain; 2014 Mar; 137(Pt 3):806-18. PubMed ID: 24430976
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.